The Goldman Sachs Group Increases Stryker (NYSE:SYK) Price Target to $427.00

Stryker (NYSE:SYK) had its price target hoisted by The Goldman Sachs Group from $384.00 to $427.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the medical technology company’s stock. The Goldman Sachs Group’s price objective suggests a potential upside of 9.24% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Truist Financial lifted their price target on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday. Canaccord Genuity Group raised their price objective on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday. Stifel Nicolaus increased their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $419.37.

Stryker Trading Up 0.1 %

NYSE:SYK opened at $390.90 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker has a one year low of $314.93 and a one year high of $406.19. The business’s 50-day simple moving average is $376.56 and its 200 day simple moving average is $362.38. The stock has a market cap of $149.02 billion, a price-to-earnings ratio of 50.37, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.86% and a net margin of 13.25%. During the same quarter in the previous year, the company posted $3.46 earnings per share. As a group, sell-side analysts predict that Stryker will post 13.53 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Stryker

Several large investors have recently made changes to their positions in the business. Dunhill Financial LLC lifted its stake in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Stryker during the 3rd quarter valued at $36,000. Activest Wealth Management bought a new stake in shares of Stryker during the 4th quarter worth $36,000. Crews Bank & Trust acquired a new position in shares of Stryker in the 4th quarter worth $39,000. Finally, Hara Capital LLC acquired a new stake in shares of Stryker during the third quarter worth $42,000. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.